CCNB2 and breast cancer: For instance, based on the Cancer Genome Atlas data, CCNB2 is upregulated in advanced tumor stage and correlates with poor prognosis in breast cancer (75); also, PSMD10 is upregulated in various cancers and the use of agents directed against its protein product gankyrin has been recently indicated as a promising cancer therapeutic and preventive strategy (76).